USMLE

Bevacizumab

4,890 views
Oncology Pharm
  1. Bleomycin
  2. Dactinomycin, Actinomycin D
  3. Doxorubicin, Daunorubicin
  4. Azathioprine, 6-MP
  5. Cladribine
  6. Cytarabine
  7. Busulfan
  8. Cyclophosphamide, Ifosfamide
  9. Nitrosoureas
  10. Paclitaxel
  11. Vincristine, Vinblastine
  12. Cisplatin, Carboplatin, Oxaliplatin
  13. Etoposide, Teniposide
  14. Irinotecan, Topotecan
  15. Bevacizumab
  16. Erlotinib
  17. Cetuximab, Panitumumab
  18. Imatinib, Dasatinib
  19. Rituximab
  20. Bortezomib, Carfilzomib
  21. Trastuzumab
  22. Dabrafenib, Vemurafenib
  23. Raloxifene and Tamoxifen
  24. Hydroxyurea
  25. Procarbazine

Summary

Bevacizumab is a monoclonal antibody against VEGF, and by inhibiting VEGF, bevacizumab inhibits angiogenesis. This inhibition of angiogenesis makes bevacizumab useful for treating solid tumors--since solid tumors need a blood supply to grow. Bevacizumab is also useful for treating wet age-related macular degeneration, which is caused by abnormal development of blood vessels in the eye. Patients taking bevacizumab are at risk for hemorrhage, impaired wound healing, and blood clots.

Key Points

  • Bevacizumab
    • Mechanism
      • Monoclonal antibody against VEGF
        • → inhibits angiogenesis
    • Clinical use
      • Solid tumors
        • Colorectal cancer, renal cell carcinoma
      • Wet age-related macular degeneration
    • Adverse Effects
      • Hemorrhage
      • Blood clots
      • Impaired wound healing